GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (TSXV:IPCI) » Definitions » Shiller PE Ratio

IntelliPharmaCeutics International (TSXV:IPCI) Shiller PE Ratio : (As of May. 21, 2024)


View and export this data going back to 1999. Start your Free Trial

What is IntelliPharmaCeutics International Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


IntelliPharmaCeutics International Shiller PE Ratio Historical Data

The historical data trend for IntelliPharmaCeutics International's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Shiller PE Ratio Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of IntelliPharmaCeutics International's Shiller PE Ratio

For the Biotechnology subindustry, IntelliPharmaCeutics International's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Shiller PE Ratio falls into.



IntelliPharmaCeutics International Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

IntelliPharmaCeutics International's E10 for the quarter that ended in Aug. 2023 is calculated as:

For example, IntelliPharmaCeutics International's adjusted earnings per share data for the three months ended in Aug. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Aug. 2023 (Change)*Current CPI (Aug. 2023)
=-0.081/125.3885*125.3885
=-0.081

Current CPI (Aug. 2023) = 125.3885.

IntelliPharmaCeutics International Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201311 -3.251 97.182 -4.195
201402 0.995 98.051 1.272
201405 -1.525 99.394 -1.924
201408 -0.765 99.315 -0.966
201411 -0.680 99.078 -0.861
201502 -0.500 99.078 -0.633
201505 -0.731 100.263 -0.914
201508 -1.052 100.579 -1.311
201511 -1.726 100.421 -2.155
201602 -1.242 100.421 -1.551
201605 -1.036 101.765 -1.276
201608 -0.910 101.686 -1.122
201611 -1.881 101.607 -2.321
201702 -0.918 102.476 -1.123
201705 -0.816 103.108 -0.992
201708 -1.046 103.108 -1.272
201711 -0.984 103.740 -1.189
201802 -1.146 104.688 -1.373
201805 -0.090 105.399 -0.107
201808 -1.187 106.031 -1.404
201811 -0.528 105.478 -0.628
201902 -0.211 106.268 -0.249
201905 -0.135 107.927 -0.157
201908 -0.093 108.085 -0.108
201911 -0.066 107.769 -0.077
202002 -0.106 108.559 -0.122
202005 -0.056 107.532 -0.065
202008 0.053 108.243 0.061
202011 -0.078 108.796 -0.090
202102 -0.051 109.745 -0.058
202105 -0.049 111.404 -0.055
202108 -0.050 112.668 -0.056
202111 -0.075 113.932 -0.083
202202 -0.038 115.986 -0.041
202205 -0.039 120.016 -0.041
202208 -0.013 120.569 -0.014
202211 -0.027 121.675 -0.028
202302 -0.013 122.070 -0.013
202305 -0.003 124.045 -0.003
202308 -0.081 125.389 -0.081

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


IntelliPharmaCeutics International  (TSXV:IPCI) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


IntelliPharmaCeutics International Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (TSXV:IPCI) Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (TSXV:IPCI) Headlines

No Headlines